DOMH

SEC Filing Summary: Spherix Incorporated (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2002, for Spherix Incorporated (formerly Biospherics Incorporated). The company operates two primary segments: InfoSpherix (information technology and reservation services) and BioSpherix (biotechnology, including the FlyCracker pesticide and Naturlose tagatose). The filing notes a change in accounting presentation for 2002, where indirect costs for the Information Technology Division are now classified as direct contract costs rather than selling, general, and administrative expenses.

Key Financial Metrics

Liquidity: The company holds $8.58 million in cash and cash equivalents. A $2 million bank line of credit with Bank of America has $1.7 million available. The company is in compliance with all bank covenants.

Material Changes vs. Prior Period

• Revenue Decline: Revenue for the six months ended June 30, 2002, decreased to $7.29 million from $10.06 million in the prior year. This 28% drop is primarily attributed to the InfoSpherix segment, which saw a $2.78 million decrease due to the absence of a one-time $1.3 million settlement revenue from the U.S. Department of Labor recognized in 2001 and a 90% drop in commercial contract revenue.
• Profitability Shift: The company reported a net loss of $1.41 million for the six-month period in 2002, compared to a net income of $132,000 in the same period in 2001.
• Segment Performance:
  • InfoSpherix: Recorded an operating loss of $765,000 for the six months, compared to an operating income of $358,000 in 2001.
  • BioSpherix: Revenue increased slightly (32% for six months) due to FlyCracker sales, but operating losses widened significantly (116% increase) due to increased R&D spending on Naturlose and sales expansion efforts.
• Cash Flow: Net cash used in operating activities increased to $1.81 million (from $1.08 million used in 2001). However, financing activities provided $4.12 million, primarily from the exercise of warrants, resulting in a net cash increase of $2.0 million for the period.

Outlook, Risks, and Contingencies

• Legal Proceedings: In May 2002, Spherix initiated arbitration against its tagatose licensee, MD Foods amba (now Arla Foods), seeking damages for delays in bringing the product to market and measures to accelerate commercialization.
• Future Revenue: Management anticipates royalties from Arla Foods could begin in 2003. The company expects sufficient cash flow from operations to cover capital needs in the near term.
• Capital Structure: The company raised approximately $3.9 million in the first half of 2002 through the exercise of warrants by an institutional investor. No dividends are anticipated in 2002.
• Market Risk: The company has minimal fixed-rate debt ($6,000) and variable-rate debt ($271,000). A 1% change in interest rates would impact net interest income by less than $85,000.

Investor Verification Checklist

• Revenue Sustainability: Verify the extent to which the 2001 revenue included non-recurring government settlement funds and assess the pipeline for new commercial contracts in the InfoSpherix segment.
• BioSpherix Burn Rate: Monitor the trajectory of R&D and sales expenses for FlyCracker and Naturlose relative to the modest revenue growth in this segment.
• Arbitration Outcome: Track the status of the arbitration against Arla Foods, as a favorable outcome could impact future royalty timelines and potential damages.
• Debt Covenants: Confirm continued compliance with the Bank of America line of credit covenants regarding tangible net worth and cash flow coverage ratios.